TY - JOUR
T1 - Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus
AU - Lin, Gu-Lung
AU - Drysdale, Simon B
AU - Snape, Matthew D
AU - O'Connor, Daniel
AU - Brown, Anthony
AU - MacIntyre-Cockett, George
AU - Mellado-Gomez, Esther
AU - de Cesare, Mariateresa
AU - Bonsall, David
AU - Ansari, M Azim
AU - Öner, Deniz
AU - Aerssens, Jeroen
AU - Butler, Christopher
AU - Bont, Louis
AU - Openshaw, Peter
AU - Martinón-Torres, Federico
AU - Nair, Harish
AU - Bowden, Rory
AU - Golubchik, Tanya
AU - Pollard, Andrew J
AU - RESCEU Investigators
A2 - Fischer, Thea Kølsen
N1 - © 2021. The Author(s).
PY - 2021/8/26
Y1 - 2021/8/26
N2 - Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children globally, but little is known about within-host RSV diversity. Here, we characterised within-host RSV populations using deep-sequencing data from 319 nasopharyngeal swabs collected during 2017-2020. RSV-B had lower consensus diversity than RSV-A at the population level, while exhibiting greater within-host diversity. Two RSV-B consensus sequences had an amino acid alteration (K68N) in the fusion (F) protein, which has been associated with reduced susceptibility to nirsevimab (MEDI8897), a novel RSV monoclonal antibody under development. In addition, several minor variants were identified in the antigenic sites of the F protein, one of which may confer resistance to palivizumab, the only licensed RSV monoclonal antibody. The differences in within-host virus populations emphasise the importance of monitoring for vaccine efficacy and may help to explain the different prevalences of monoclonal antibody-escape mutants between the two subgroups.
AB - Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children globally, but little is known about within-host RSV diversity. Here, we characterised within-host RSV populations using deep-sequencing data from 319 nasopharyngeal swabs collected during 2017-2020. RSV-B had lower consensus diversity than RSV-A at the population level, while exhibiting greater within-host diversity. Two RSV-B consensus sequences had an amino acid alteration (K68N) in the fusion (F) protein, which has been associated with reduced susceptibility to nirsevimab (MEDI8897), a novel RSV monoclonal antibody under development. In addition, several minor variants were identified in the antigenic sites of the F protein, one of which may confer resistance to palivizumab, the only licensed RSV monoclonal antibody. The differences in within-host virus populations emphasise the importance of monitoring for vaccine efficacy and may help to explain the different prevalences of monoclonal antibody-escape mutants between the two subgroups.
UR - https://www.scopus.com/pages/publications/85113609359
U2 - 10.1038/s41467-021-25265-4
DO - 10.1038/s41467-021-25265-4
M3 - Journal article
C2 - 34446722
SN - 2041-1723
VL - 12
SP - 5125
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5125
ER -